Pacific Biosciences of California, Inc. (PACB)

Market Cap	450.37M +53.0%
Revenue (ttm)	160.03M +5.0%
Net Income	-128.58M
EPS	-0.43
Shares Out	310.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,483,634
Open	1.600
Previous Close	1.630
Day's Range	1.390 - 1.620
52-Week Range	0.987 - 2.730
Beta	2.32
Analysts	Buy
Price Target	2.46 (+69.66%)
Earnings Date	May 7, 2026

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 27, 2010
• Employees: 485
• Stock Exchange: NASDAQ
• Ticker Symbol: PACB
• Website: https://www.pacb.com

Financial Performance

In 2025, PACB's revenue was $160.01 million, an increase of 3.89% compared to the previous year's $154.01 million. Losses were -$546.38 million, 76.3% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for PACB stock is "Buy." The 12-month stock price target is $2.46, which is an increase of 69.66% from the latest price.

Price Target

$2.46

(69.66% upside)

Analyst Consensus: Buy